Physician

Damian Silbermins, MD

According to 2025 Medicare claims, Damian Silbermins, MD (NPI: 1922207117) practices hematology/oncology in the Huntington-Ashland, WV-KY-OH market, with the plurality of this provider's patient population coming from Cabell, WV. This provider's primary affiliated billing organization is ST. MARY'S HIMG, LLC (NPI: 1184233454; TIN: 85-2017234) and primary practice location at 25705-8859. Silbermins is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Silbermins' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 499 traditional Medicare patients, billed 2,604 HCPCS/CPT codes, and received $144,565 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,408 prescription claims across 382 beneficiaries totaling $5,273,086 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 41 claims. Open Payments data shows 185 records totaling $33,716. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $1,067,731 to $144,565. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,013,479 to $5,273,086. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $6,329 and ending at $597.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	489	105,079	$1,067,731
2016	515	142,179	$1,137,049
2017	502	143,363	$1,580,843
2018	550	173,280	$1,622,983
2019	551	196,805	$1,857,080
2020	505	111,070	$1,114,888
2021	465	1,502	$119,857
2022	549	1,714	$129,816
2023	511	1,711	$130,436
2024	499	2,604	$144,565

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	236	1,843	$2,013,479
2016	235	1,922	$2,026,909
2017	239	1,680	$1,797,458
2018	258	1,610	$2,165,306
2019	256	1,545	$2,676,674
2020	273	1,892	$4,074,517
2021	290	1,955	$4,749,261
2022	339	2,132	$5,709,474
2023	353	2,221	$5,020,965
2024	382	2,408	$5,273,086

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	131	$32,563
2016	N/R	113	$4,979
2017	N/R	101	$4,516
2018	N/R	162	$15,003
2019	N/R	94	$4,293
2020	N/R	219	$9,238
2021	N/R	109	$6,420
2022	N/R	168	$8,763
2023	N/R	41	$1,907
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	137	149	$131
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	123	294	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	252	671	$72
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	158	204	$46
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	308	995	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	46	1,169	$695,452
Brukinsa	Zanubrutinib	52	1,560	$688,785
Tibsovo	Ivosidenib	16	480	$531,546
Xtandi	Enzalutamide	25	720	$352,214
Tagrisso	Osimertinib Mesylate	21	600	$329,124

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	184	$32,966	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$750	Amgen Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Damian Silbermins, MD?

Tedicare shows public-source Medicare data for Damian Silbermins, MD (NPI 1922207117), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Damian Silbermins, MD have ACO affiliation data?

Damian Silbermins, MD is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Damian Silbermins, MD?

Damian Silbermins, MD is linked to ST. MARY'S HIMG, LLC (billing NPI 1184233454) in the available physician profile data.

Does Damian Silbermins, MD have Open Payments data?

Damian Silbermins, MD has 185 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.